Unlike older therapies that target one or two receptors, Retatrutide activates three receptors: GLP-1, GIP, and glucagon
This additional mechanism may promote weight loss even more by improving digestion, a broader and potentially more effective approach than semaglutide
Purity standards are the same, but achieving those standards with a 39-amino acid chain is harder than with a 31-amino acid chain
Exploration of Drug Science
Microdosing Semaglutide, which is less than the standard dosage, can start affecting appetite and blood sugar within a few weeks, but noticeable effects are usually milder and take longer
Earlier evidence for retatrutide comes from a Phase 2 trial in NEJM in 2023, which reported 24.2% weight loss at 12 mg over 48 weeks